Development of an Inactivated Vaccine Candidate, BBIBP-CorV, with Potent Protection against SARS-CoV-2

Hui Wang(Weifang Medical University), Xiaoming Yang(Shanghai Municipal Center For Disease Control Prevention), Hongyang Liang(National Vaccine and Serum Institute), George F. Gao(Chinese Academy of Sciences), Wei Deng(Center for Excellence in Brain Science and Intelligence Technology), Zhengli Zhang(National Vaccine and Serum Institute), Guizhen Wu(Chinese Center For Disease Control and Prevention), Changgui Li(National Institutes for Food and Drug Control), Peihua Niu(National Institute for Viral Disease Control and Prevention), Wenjie Tan(Sinopec (China)), Baoying Huang(National Institute for Viral Disease Control and Prevention), Jin Zhang(Wuhan Institute of Bioengineering), Linlin Bao(Chinese Academy of Medical Sciences & Peking Union Medical College), Shouzhi Yu(National Vaccine and Serum Institute), Zhiyong Lou(Tsinghua University), Guangxue Xu(Tsinghua University), Ling Ding(Shanghai Medical College of Fudan University), Yaru Quan(National Institutes for Food and Drug Control), Na Li(Macau University of Science and Technology), Miao Xu(National Center for Advancing Translational Sciences), Wenling Wang(Chinese Academy of Sciences), Hong Gao(Institute of Laboratory Animal Science), Yanfeng Xu(Chinese Academy of Medical Sciences & Peking Union Medical College), Wenbo Xu(Shenyang Institute of Automation), Weimin Zhou(Chinese Center For Disease Control and Prevention), Chuan Qin(Chinese Academy of Medical Sciences & Peking Union Medical College), Yuxiu Zhao(National Vaccine and Serum Institute), Hui Fu(Huazhong University of Science and Technology), Jiangning Liu(Chinese Academy of Medical Sciences & Peking Union Medical College), Yuntao Zhang(National Vaccine and Serum Institute), Li Zhao(BGI Group (China))
Cited by 802


Related Papers